Meeting Announcement: Cancer Immunotherapy and Combinations June 15-16 2016
Reporter: Stephen J. Williams, PhD
|
Cancer Immunotherapy & Combinations – June 15-16, 2016 in Boston, MA
Final Brochure PDF | Learn More | Sponsorship & Exhibit Details | Register by March 4 & SAVE up to $400! Cambridge Healthtech Institute’s inaugural Cancer Immunotherapy and Combinations meeting will convene immuno-oncology researchers, cancer immunotherapy developers, and technology providers to discuss next-generation approaches and combinations, including small molecule development, to enhance the efficacy of checkpoint inhibitors. BISPECIFIC ANTIBODIES – DUAL TARGETINGFEATURED PRESENTATION: ANTI-PD1 OR CD137 ENHANCES NK-CELL CYTOTOXICITY TOWARDS CD30+ HODGKIN LYMPHOMA INDUCED BY CD30/CD16A TANDAB AFM13 In vivo Efficacy of Bispecific Antibodies Targeting Two Immune-Modulatory Receptors Dual-Targeting Bispecific Antibodies for Selective Neutralization of CD47 on Cancer Cells Update on MCLA-134: A Biclonics® Binding Two Immunomodulatory Targets Expressed by T Cells The ImmTAC Technology: A Cutting-Edge Immunotherapy for Cancer Treatment RADIOTHERAPY AND CHEMOTHERAPY – PD-1 COMBINATIONSRational Development of Combinations of Antiangiogenic Therapy with Immune Checkpoint Blockers Using Mouse Models of HCC and Cirrhosis Harnessing the Immune Microenvironment of Gastrointestinal Cancers Using Combined Modalities AGONIST – PD-1 AND CTLA-4 COMBINATIONSThe Role of the Target in the Disposition and Immunogenicity of an Anti-GITR Agonist Antibody Combination of 4-1BB Agonist and PD-1 Antagonist Promotes Antitumor Effector/Memory CD8 T Cells Combination Immunotherapy with Checkpoint Blockade, Agonist Anti-OX40 mAb, and Vaccination Rescues Anergic CD8 T Cells Interactive Breakout Discussion Groups with Continental BreakfastThis session features various discussion groups that are led by a moderator/s who ensures focused conversations around the key issues listed. Attendees choose to join a specific group and the small, informal setting facilitates sharing of ideas and active networking. Continental breakfast is available for all participants. Topic: Small Molecule Targeting of IDO1 and TDO for Cancer Immunotherapy Moderator: Rogier Buijsman, Ph.D., Head, Chemistry, Netherlands Translational Research Center B.V. (NTRC)
Topic: Strategies for Developing Bispecific Antibodies for Cancer Immunotherapy Moderator: Krzysztof Masternak, Ph.D., Head, Biology, Therapeutic Antibody Discovery, Novimmune
Topic: Combining Standard Antiangiogenic Therapy with Immune Checkpoint Inhibitors Moderator: Dan Duda, D.M.D., Ph.D., Associate Professor, Steele Laboratories for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School
SMALL MOLECULE INHIBITORS AS SINGLE AND CHECKPOINT COMBINATION AGENTSSelective Small Molecule Inhibitors of IDO1 and TDO for Cancer Immunotherapy Potent and Selective Small Molecule USP7 Inhibitors for Cancer Immunotherapy Epigenetic Agents for Combination with Cancer Immunotherapy VACCINES AND CHECKPOINT BLOCKADE IMMUNOTHERAPYImmunotherapy for Mesothelioma with an in vivo DC Vaccine and PD-1/PD-L1 Blockade Bringing Together Checkpoint Inhibition with Vaccines Using Customizing Capsids Recommended All Access Package: June 14 SC1: Immunosequencing: Generating a New Class of Cancer Immunotherapy Diagnostics* June 14 SC5: Convergence of Immunotherapy and Epigenetics for Cancer Treatment* June 14 SC8: Rational Design of Cancer Combination Therapies* June 15-16: Cancer Immunotherapy and Combinations June 16-17: Tumor Models for Cancer Immunotherapy * Separate registration required. Exhibit booth space has sold out! The few remaining spaces are being sold via sponsorship only. To customize yoursponsorship package, please contact: For more information visit WorldPreclinicalCongress.com/Cancer-Immunotherapy-Combinations |
Cambridge Healthtech Institute, 250 First Avenue, Suite 300, Needham, MA 02494 healthtech.com
Tel: 781-972-5400 | Fax: 781-972-5425
This email is being sent to sjwilliamspa@comcast.net. This email communication is for marketing purposes. If it is not of interest to you, please disregard and we apologize for any inconvenience this may have caused.
Visit www.chicorporate.com/corporate_unsubscribe.aspx to update usage.
2012pharmaceutical
Amandeep Kaur
Aashir Awan, Phd
Abhisar Anand
Adina Hazan
Alan F. Kaul, PharmD., MS, MBA, FCCP
alexcrystal6
anamikasarkar
apreconasia
aviralvatsa
David Orchard-Webb, PhD
danutdaagmailcom
Demet Sag, Ph.D., CRA, GCP
Dror Nir
dsmolyar
Ethan Coomber
evelinacohn
Frason
Gail S Thornton
Irina Robu
jayzmit48
jdpmd
jshertok
kellyperlman
Ed Kislauskis
larryhbern
Madison Davis
marzankhan
megbaker58
ofermar2020
Dr. Pati
pkandala
ritusaxena
Rick Mandahl
sjwilliamspa
Srinivas Sriram
stuartlpbi
Dr. Sudipta Saha
tildabarliya
zraviv06
zs22
Leave a Reply